Recent advancements in cancer immunotherapy have provided new hope for patients, yet challenges remain in improving treatment efficacy. For instance, the objective response rate (ORR) of PD-1 immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) patients is approximately 30%-45%, with a complete response (CR) rate below 5%. This indicates that only a subset of patients benefit from these therapies, and long-term efficacy remains uncertain. Emerging research suggests that the gut microbiome plays a crucial role in modulating immune responses, with specific microbial compositions shown to enhance T-cell function and improve immunotherapy outcomes.
MS-20: A Next-Generation Postbiotic Approach
Taiwan-based biotech company Microbio Co., Ltd. has developed MS-20, a proprietary postbiotic formulation derived through an advanced anaerobic co-fermentation process. The latest clinical research demonstrates that combining MS-20 with PD-1 immunotherapy (Keytruda) significantly improves treatment efficacy in advanced NSCLC patients.
Clinical trial results indicate that patients receiving MS-20 in combination with Keytruda experienced a threefold increase in response rate, reaching 75%. Furthermore, the CR rate improved to 12.5%. Notably, over half of the patients in the combination therapy group remained progression-free for one year, compared to a median progression-free survival (PFS) of only 4.5 months in the Keytruda monotherapy group. These findings suggest that MS-20 effectively mitigates T-cell exhaustion, thereby enhancing immunotherapy response and improving outcomes in late-stage lung cancer patients.
Scientific Rationale and Advantages Over Traditional Microbiome Approaches
Reports in leading scientific journals, including Science Immunology, Nature Medicine, and Annals of Oncology, have highlighted the role of the gut microbiome in modulating immune responses. Specific gut bacteria have been shown to activate dendritic cells and T cells, thereby enhancing the efficacy of PD-1 inhibitors. However, conventional approaches such as fecal microbiota transplantation (FMT) face significant challenges, including donor selection and standardization issues, which limit their clinical application.
In contrast, MS-20, as a postbiotic solution, overcomes these limitations by providing a stable, well-defined, and reproducible formulation. This ensures greater consistency in modulating the gut microbiome and enhancing immunotherapy response without the variability associated with FMT.
Regulatory Recognition and Clinical Implications
MS-20 has been granted Generally Recognized as Safe (GRAS) certification by the U.S. Food and Drug Administration (FDA), confirming its safety profile for use alongside pharmaceutical treatments. This milestone underscores MS-20’s potential as a safe and effective adjunct therapy for cancer patients undergoing immunotherapy.
The breakthrough findings from MS-20 research not only offer new hope for advanced lung cancer patients but also pave the way for future advancements in cancer immunotherapy. By harnessing the power of the gut microbiome, MS-20 represents a promising innovation that may redefine the landscape of cancer treatment worldwide.
Resource: 腸道菌群新解方！中天生技MS-20提升臨床癌症免疫療法反應率3倍
